Interleukin 1 level, cognitive
performance, and severity
of depressive symptoms
in patients treated with
systemic anticancer therapy: a
prospective study by Justyna Jasionowska et al.
166
www.cmj.hr
Aim To assess the relationship between cognitive func-
tions, severity of depressive symptoms, and expression of 
interleukin 1 (IL)-1 in patients treated with systemic anti-
cancer therapy.
Methods This prospective study, conducted in 2017-2018, 
involved 55 patients (56% men) subjected to systemic 
anticancer therapy. Forty-one patients had lung cancer 
(74.55%) and 14 had breast cancer (25.45%). Patients’ mean 
age was 55.5 ± 9.3 (from 26 to 65 years). Neuropsychologi-
cal tests were conducted twice: on the day of qualifying 
for the study before the start of chemotherapy and after 
the end of the full treatment cycle. We assessed patients’ 
cognitive functioning using Trail Making Test A&B (TMT), 
Stroop Color-Word Interference Test, and Verbal Fluency 
Test (VFT). Severity of depressive symptoms and the level 
of IL-1 expression were also examined.
Results After chemotherapy, patients had significantly 
lower expression of IL-1α (P < 0.005) and IL-1β (P < 0.001) at 
the protein level. They also had lower severity of depressive 
symptoms (borderline significant, P = 0.063), needed more 
time to complete the first part of the Stroop test (P = 0.03), 
and had worse score on the first part of the VFT (P < 0.001). 
Before chemotherapy there was a significant negative cor-
relation between IL-1β expression and the speed at which 
the first part of the TMT test was completed.
Conclusions The severity of depressive symptoms after 
chemotherapy was lower than before chemotherapy. Pa-
tients’ cognitive performance did not significantly deteri-
orate after chemotherapy, except the performance at the 
first part of the Stroop test and the first part of the VFT.
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The cancer incidence in Europe is particularly high – about 
20% of all cancer deaths and almost 25% of cases of cancer 
worldwide are recorded in Europe (1). In this sense, Poland 
is no exception; in 2015, malignant cancer was the sec-
ond most common cause of death among Polish citizens 
(about 27% of all deaths in men and 24% in women) (2). 
Cancer is also the most common cause of premature mor-
tality, particularly among women, accounting for as much 
as 33% of deaths among young women and about 50% 
of deaths among middle-aged women. According to the 
Polish National Cancer Registry, there were slightly more 
than 159 200 new cases and about 95 600 cancer deaths 
in 2014 (3).
One of the side effects of systemic anticancer therapy 
are changes in cognitive function, referred to as chemo-
brain, chemofog, or chemotherapy-related cognitive 
impairment (4,5). This phenomenon is characterized by 
impaired visual and verbal memory, working memory, 
concentration, language skills, response time, and mo-
tor skills (5,6). Chemobrain affects from 17% to 75% of 
all cancer patients subjected to therapy (6) and is usu-
ally mild and transient, with escalation during anticancer 
treatment.
Although most studies indicate that chemobrain symp-
toms are short-term, it was reported that in 35% of patients 
with cancer remission they persisted for several years (7). 
The etiology of chemobrain is complex and non-uniform, 
with influencing factors ranging from those related to the 
presence of cancer and its treatment process to patient-
related ones (6). The causes of cognitive disorders after 
chemotherapy include changes in central nervous system 
metabolism, damage to neurons, decrease in neurotrans-
mitters activity, impact of procedures such as anesthesia, 
use of additional pharmacological agents, coexisting dis-
eases, as well as changes in the release of proinflammatory 
cytokines, which have recently been of particular interest 
among researchers (6,8). Cytostatic drugs are believed to 
marginally cross the blood-brain barrier, but their neuro-
toxic effects are probably related to the action of proin-
flammatory cytokines (9).
The mechanism of cognitive changes induced by cytokine 
action in the central nervous system is not fully under-
stood. There are studies describing a sudden increase in 
the level of cytokines during the day after chemotherapy 
(10). Cognitive impairment is often described as an ele-
ment of the so-called sickness behavior characterized by 
an increase in cytokines such as interleukin 1 (IL-1), inter-
leukin 2 (IL-2), or tumor necrosis factor alpha (TNF-α). This 
phenomenon is one of the etiological factors of depressive 
disorders (6). In the hippocampus and other regions rich 
in receptors for cytokines, these protein mediators can in-
duce inflammation through the oxidative mechanism and 
nitrosative mechanism (9). A relationship between a slight-
ly intensified inflammatory state and a decrease in the hip-
pocampus volume, which deteriorates memory functions, 
was also described (11,12). Changes in the hippocampus 
structure in the dominant hemisphere reduce the ability 
to learn and store information in memory, as well as the 
ability to recognize verbal material presented in a visual or 
auditory form (12).
In order to better understand the influence of cytokines, 
namely IL-1, on changes in cognitive processes associat-
ed with anticancer chemotherapy, we assessed the im-
pact of chemotherapy-induced inflammatory reaction on 
cognitive functions, as well as on the severity of depres-
sive symptoms. According to our knowledge, this is the 
first study on this issue, analyzing all three variables: level 
of interleukins, severity of depression, and cognitive per-
formance among patients with cancer.
MATErIAl And METhodS
Patients
The study, conducted in 2017-2018, included patients hos-
pitalized at the Department of Chemotherapy with the 
Sub-unit of Diagnostics and Oncological Therapy of the 
Regional Oncological Centre at the Voivodeship Special-
ist Hospital and the Department of Oncological Surgery of 
the Polish Mother’s Memorial Hospital Research Institute 
in Lodz.
The study started on March 1, 2017 (FPFV date) and ended 
on October 31, 2018 (LPLV date). Patients hospitalized in 
the mentioned wards were included in the study if they 
met the inclusion and exclusion criteria and agreed to par-
ticipate in the study. Sixty-three people were included in 
the first stage of the study (60.32% men). Eight patients 
left the study without giving a reason (5 with lung cancer 
and 3 with breast cancer). In this group, only the first stage 
of the study was performed. Obtained results were not in-
cluded in statistical analyzes.
The inclusion criteria were age between 25 and 65 years 
and the diagnosis of lung cancer or breast cancer not 
earlier than one month before the enrollment in the 
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study. The exclusion criteria were metastases to the cen-
tral nervous system, completed palliative and elective ra-
diotherapy of the central nervous system, history of diag-
nosed axis I or II mental disorders (before commencement 
of cancer management), central nervous system traumas, 
inflammatory or autoimmune disorders, the level of in-
tellectual functioning below average, excessive use of or 
addiction to psychoactive substances, pharmacotherapy 
that may negatively affect cognitive performance (besides 
chemotherapy), and unwillingness to give informed con-
sent. Patients’ eligibility for the study was assessed by the 
same person – an oncologist. Medical data on the course 
of the disease were obtained directly from the patients, 
from attending physicians, and from medical records 
(with patients’ consent). Ultimately, those who agreed to 
participate in the study and underwent the entire treat-
ment cycle were qualified to participate in the study 
(N = 55, 56% men). Each patient gave a written consent to 
participate in the study, and the study was approved by 
the Bioethics Committee of the Medical University of Lodz 
(No. RNN/497/13/KB).
The authors were not involved in the process of diagno-
sis or treatment at any stage of the study. Forty-one pa-
tients had lung cancer (74.55%) and 14 had breast can-
cer (25.45%). Patients’ mean age was 55.5 ± 9.3 years and 
ranged from 26 to 65 years.
Pharmacotherapeutic agents used were cycle-specific 
agents that destroy mainly cells in the cellular cycle, but 
provide lower effectiveness in relation to the G0 phase (cis-
platin, carboplatin) and phase-specific agents that destroy 
cells in a particular cycle phase (antimetabolites: gemcit-




The patients underwent the neuropsychological tests 
twice: on the day of qualifying for the study before the start 
of chemotherapy and after the end of the full treatment 
cycle. Cognitive performance was assessed by the same 
person (clinical psychologist, neuropsychologist). The av-
erage time between the first and the second stage of the 
study was 18 weeks. The second stage of the study took 
place within a week of taking the last dose of the drug. 
Only patients who completed the entire treatment cy-
cle were included in the statistical analysis.
We analyzed the performance of information processing 
speed (Trail Making Test A & B, TMT), working memory and 
executive functions (TMT, the Stroop Color-Word Inter-
ference Test, verbal fluency test, VFT), and verbal fluency 
(VFT) (13). We wanted to ensure that participation in the 
study was not an additional burden for the patients. We 
created a parallel version of VFT for the assessment after 
chemotherapy because the participants were already fa-
miliar we the first version (the first version of the VFT in-
cluded animals, words beginning with the letter “k” and “s”; 
the second version of the VFT included plants, words be-
ginning with the letter “m” and “p”).
Assessment of severity of recurrent depressive disorder 
symptoms
To evaluate the dynamics of severity of recurrent de-
pressive disorder symptoms both before and after che-
motherapy we used Hamilton Depression Rating Scale 
(HDRS, HAM-D) (14). We also used the CIDI questionnaire 
(version 3.0) (15), to assess the patient’s eligibility for the 
study.
determination of Il-1α and Il-1β expression at the 
mrnA and protein level
Ten mL of venous blood (two 5 mL test tubes) were collect-
ed by qualified medical personnel using sterile and dispos-
able equipment, both before and after the chemotherapy. 
The procedure of IL-1α and IL-1β expression level assess-
ment was described in detail in a previous study (16).
Statistical analysis
Normality of distribution was tested with the Shapiro–
Wilk test. The groups were compared using the Wilcox-
on matched pairs test with the Bonferroni correction in 
each case. The correlations between the analyzed vari-
ables were evaluated using Spearman’s rank correlation 
coefficient. The level of statistical significance was set at 
P < 0.05 (17). The statistical analysis was performed with 
STATISTICA PL, version 13.1 (StatSoft Polska Sp., Krakow, 
Poland).
rESulTS
Patients before chemotherapy had somewhat greater se-
verity of depressive symptoms than after chemotherapy, 
ie, the difference was borderline significant (P = 0.06) (Table 
1). The mean severity of depressive symptoms before che-
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motherapy met the criteria of a mild depressive episode, 
while the mean the severity after chemotherapy did not 
reach the level of diagnostic significance. The expression 
of IL-1α (Z = 4.63, P < 0.005) and IL-1β (Z = 5.32, P < 0.001) at 
the protein level significantly decreased after chemother-
apy (Table 1).
Assessment of cognitive performance
No differences were found in the performance on TMT test 
before and after chemotherapy. For the Stroop Color-Word 
Interference Test and the Verbal Fluency Test, the differenc-
es were significant only for the first part of the tests. Pa-
tients after chemotherapy needed significantly more time 
to complete the first part of the Stroop test (RCNb-reading 
color name in black) (P = 0.03). They also had a significantly 
worse score on the first part of the Verbal Fluency Test (se-
mantic category) (P < 0.001) (Table 2).
Correlations
Before chemotherapy, there were some weak and non-
significant correlations – between increased IL-1α ex-
pression at the mRNA and protein levels and both sever-
ity of depressive symptoms and cognitive performance 
impairment in each of the tests conducted and between 
increased IL-1 β expression at the mRNA and protein lev-
els and lower depressive symptoms and better cognitive 
performance on the third part of VFT (part c). A significant 
negative correlation was observed between IL-1β expres-
sion and the speed at which the first part of the TMT test 
was performed (Table 3).
After chemotherapy, an increased IL-1α expression at the 
mRNA and protein levels weakly and non-significantly cor-
related with both severity of depressive symptoms and 
cognitive performance impairment in each of the tests 
TAblE 1. The severity of depressive symptoms and expression of interleukin (Il)-1α and Il-1β in patients with cancer before and after 
systemic anticancer therapy
before After
Variable median (IQr) minimum maximum median (IQr) minimum maximum Z* P*
Hamilton Depression Rating Scale 8 (5-13) 1.00 19.00 5 (3-7) 0.00 26.00 1.857 0.063
IL-1α mRNA (2-ΔΔct) 0.177 (0.142-0.21) 0.11  0.28 - - - - -
IL-1α protein (pg/mL) 8.841 (6.790-10.36) 5.54 14.19 7.431 (6.661-9.871) 4.69 12.23 4.631 <0.005
IL-1β mRNA (2-ΔΔct) 0.039 (0.036- 0.05) 0.02  0.11 - - - - -
IL-1β protein (pg/mL) 1.981 (1.741-2.19) 1.19  3.13 1.815 (1.631-2.151) 1.28  2.75 5.316 <0.001
*the Wilcoxon test.
TAblE 2. Cognitive performance in patients with cancer before and after systemic anticancer therapy*
before After





21.00  59.00 30.51 
(26-38)
22.00 135.00 2.228  0.03




41.00 112.00 56.51 
(51.51-72.51)





 8.00  34.00 11  
(10-18)





 4.00  16.00 10.51  
(8-13)





 3.00  25.00 11  
(8.5-16.5)
 1.00  21.00 0.417  0.68




16.00 100.00 36 
(22-44)
13.00 104.00 0.524  0.76




44.00 245.00 84 
(60-112)
36.00 174.00 1.591  0.11
*rCnb – reading color names in black; nCWd – naming color of word – different; TMT – Trail Making Test; before – on the day of qualifying for the 
study before the start of chemotherapy; after – after the end of the full treatment cycle.
†the Wilcoxon test
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conducted. In the case of IL-1β, there was no significant 
correlation for any of the analyzed variables (Table 4).
dISCuSSIon
We did not find any significant deterioration in the pa-
tients’ cognitive performance after the chemotherapy 
cycle. However, the severity of depressive symptoms de-
creased. Both before and after chemotherapy there was a 
non-significant relationship between the IL-1α expression 
at the mRNA and protein level with the severity of depres-
sive symptoms and cognitive performance impairment in 
each of the tests conducted.
The studies conducted so far present a wide range of re-
sults concerning the severity of depressive symptoms in 
cancer patients undergoing chemotherapy, which may 
result from the variety of methods used. The majority 
of studies dealing with this topic indicate that patients 
with cancer diagnosis more often have depressive dis-
orders than the general population (18). Zielińska-
Więczkowska and Betłakowski demonstrated that the se-
verity of depressive symptoms among cancer patients was 
higher after chemotherapy than before chemotherapy 
(19). In the present study, we found that the severity of de-
pressive symptoms diminished after the completed che-
motherapy cycle compared to the value before the start 
of treatment. This finding can be explained by the fact that 
the treatment completion, or even part of it, gives the pa-
tient hope for a cure. Colleoni et al (20) showed that the 
occurrence of depressive disorders in patients with cancer 
influenced the decision to start treatment and its effective-
ness.
In this study, the expression of both IL-1α and IL-1β at the 
protein level decreased after chemotherapy. The literature 
indicates that IL-1β stimulates the formation of other cytok-
ines, eg, IL-2, INF-gamma by T lymphocytes, as well as IL-6 
(21). IL-1 and IL-6, among others, regulate the acute phase 
reaction (22). An increase in IL-1β value was observed in 
patients with neurodegenerative diseases, eg, Alzheimer 
disease (23,24). In addition, its increase was associated with 
TAblE 3. Correlations between Il-1α and Il-1β levels, hamilton depression rating Scale (hdrS) score, and cognitive performance in 
patients with cancer before systemic anticancer therapy*
Il-1α mrnA (2-ΔΔct) Il-1α protein (pg/ml) Il-1β mrnA (2-ΔΔct) Il-1β protein (pg/ml)
Variable Spearman’s rho P Spearman’s rho P Spearman’s rho P Spearman’s rho P
HDRS 0.046 0.760 0.004 0.977 -0.193 0.195 -0.222 0.133
Stroop Test RCNb time (seconds) -0.063 0.675 -0.053 0.722 0.062 0.677 0.082 0.583
Stroop Test NCWd time (seconds) -0.166 0.265 -0.128 0.390 0.172 0.248 0.030 0.842
Fluency  part a -0.178 0.231 -0.183 0.218 -0.241 0.103 -0.244 0.098
Fluency  part b -0.102 0.494 -0.097 0.516 -0.191 0.198 -0.116 0.436
Fluency  part c -0.021 0.888 -0.020 0.896 0.115 0.441 0.227 0.126
TMT part A time (seconds) 0.062 0.684 0.067 0.657 -0.113 0.453 -0.310 0.036
TMT part B time (seconds) 0.047 0.754 0.032 0.832 -0.005 0.971 -0.161 0.285
*hdrS – hamilton depression rating Scale; rCnb – reading color names in black; nCWd – naming color of the word – different; TMT – Trail Making 
Test.
TAblE 4. Correlations between Il-1α and Il-1β levels, hamilton depression rating Scale (hdrS) score, and cognitive performance in 
patients with cancer after systemic anticancer therapy*
Il-1α protein (pg/ml) Il-1β protein (pg/ml)
Variable Spearman’s rho P Spearman’s rho P
HDRS 0.055 0.740 -0.234 0.152
Stroop Test RCNb time (seconds) -0.007 0.969 0.090 0.586
Stroop Test NCWd time (seconds) -0.034 0.836 0.135 0.411
Fluency part a -0.181 0.270 -0.290 0.073
Fluency part b -0.047 0.777 -0.072 0.662
Fluency part c -0.008 0.961 0.216 0.187
TMT part A time (seconds) 0.145 0.385 -0.239 0.148
TMT part B time (seconds) 0.004 0.982 0.091 0.588
*hdrS – hamilton depression rating Scale; rCnb – reading color names in black; nCWd – naming color of word – different; TMT – Trail Making Test.
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the deterioration of age-related cognitive functions, such 
as reduced learning ability or memory deficits (25,26). Also 
Meyers et al showed in patients with acute myeloid leuke-
mia and myelodysplastic syndrome treated with chemo-
therapy, significantly elevated levels of IL-1, IL-6, IL-8, TNF-
alpha, compared to the control group (27).
We did not find a significant relationship between the 
level of interleukins and participants’ cognitive efficiency. 
Chung et al (9) found that an increase in plasma concen-
tration of IL-1β was associated with a decrease in the speed 
of response on neuropsychological tests, while an increase 
in IL-4 concentration was associated with an increase in re-
sponse rates. Furthermore, with an increase in IL-1β and 
IL-6 levels, the changes in cognitive functions were more 
noticeable to the patients themselves (9).
Numerous studies conducted so far to evaluate cognitive 
functions after chemotherapy present divergent data on 
this subject, both confirming and denying the existence 
of these disorders. In addition, a significant obstacle is the 
lack of standard testing methods. This cognitive deficit is 
often referred to as mild, and attention is also drawn to its 
possible subjective nature, as it is often not confirmed by 
psychological tests. Moreover, there are reports highlight-
ing that cognitive disorders exist before treatment (6) and 
therefore are not related to treatment (28). The analysis of 
cognitive performance in our study also provided ambig-
uous results. Andryszak (29) found that 43% of the stud-
ies in breast cancer patients found a lack of chemother-
apy-dependent cognitive function disorders, while other 
studies found deficits involving attention, working and 
visual memory, processing ability, learning, and speech 
function (29). Interestingly, the overwhelming number of 
these studies did not confirm the relationship between 
depressive state and anxiety and cognitive function de-
terioration (29). However, Bury et al found non-specific 
changes in cognitive functions as well as higher severity 
of depressive symptoms in patients treated with chemo-
therapy compared with healthy participants (30), while 
Wefel et al demonstrated a relationship between distress 
and impairment of cognitive function in 35% of patients 
with breast cancer before supplementary treatment (31). 
In our study, we confirmed a decrease in cognitive per-
formance after chemotherapy only in the Stroop test and 
one part of the verbal fluency test. So far, it has not been 
clearly defined which of the elements of cognitive func-
tions that are reduced after chemotherapy are particularly 
characteristic for it. Some studies found that visual and 
spatial skills (32-34), working memory, depressive symp-
toms (33), visual memory, verbal learning ability (34), and 
language and memory functions (35) to be significantly 
affected.
Many studies have attempted to find a relationship be-
tween the level of cytokines and changes in cognitive 
functions as well as the severity of depressive disorders af-
ter the systemic treatment in patients suffering from can-
cer. Although most of them showed some deviations in 
cytokine concentration due to chemotherapy, the results 
concerning the relationship between cytokine levels and 
modification of cognitive functions are not clear (36,37). It 
seems that several methodological problems (eg, variety 
of research tools used, size of the studied groups) prevent 
the correct interpretation of the available data on chemo-
brain occurrence. Therefore, it is necessary to carry out fur-
ther studies to assess the deficit in cognitive functions in 
patients with cancer in order to determine the prevalence 
of this phenomenon (38).
The limitations of the study are the size of the studied 
groups, as well as the disproportions in the demographic 
distribution of study participants in each of them (sex).
It is important to expand the research into the relationship 
between immune system components (cytokines) and se-
verity of depression in cancer patients treated with chemo-
therapy. Depression is one of the most common disorders 
associated with cancer, with many mutual two-way mech-
anisms of action. Another important issue is the chemo-
brain phenomenon. Some studies indicate that cancer-
related cognitive disorders may be long-lasting and occur 
even after 5 to 10 years after treatment (39). Owing to the 
complexity and prevalence of the chemobrain phenom-
enon, it is necessary to seek further relationships between 
cognitive function deficits and the applied chemotherapy 
in patients with cancer.
oxford Centre for Evidence-based Medicine level of evidence 2 (or level b).
Funding The research was financed with scientific research grants awarded 
by the Medical University of Lodz No. 502-03/5-062-02/502-54-208 and No. 
503/5-062-02/503-51-010-18.
Ethical approval given by the Bioethics Committee of the Medical Univer-
sity of Lodz (No. RNN/497/13/KB).
declaration of authorship JJ and MT conceived and designed the study; 
EK, AS, and IM acquired the data; JJ, MT, and JS analyzed and interpreted 
the data; JJ and MT drafted the manuscript; MT and PG critically revised the 
manuscript for important intellectual content; JJ, MT, EK, JS, and PG gave 
approval of the version to be submitted.
Competing interests All authors have completed the Unified Competing 
Interest form at www.icmje.org/coi_disclosure.pdf (available on request 
from the corresponding author) and declare: no support from any or-
ganization for the submitted work; no financial relationships with 
RESEARCH ARTICLE172 Croat Med J. 2019;60:166-73
www.cmj.hr
any organizations that might have an interest in the submitted work in the 
previous 3 years; no other relationships or activities that could appear to 
have influenced the submitted work.
references
1 International Agency for research of Cancer. Press release n0263. 
latest global cancer data: Cancer burden rises to 18.1 million new 
cases and 9.6 million cancer deaths in 2018. September 2018. 
Available from: http://www.iarc.fr/en/media-centre/pr/2018/pdfs/
pr263_E.pdf. Accessed: March 29, 2019.
2 Supreme Audit office, department of health. Availability and 
effects of cancer treatment, 2018 [in Polish]. Available from: 
https://www.nik.gov.pl/plik/id,15932,vp,18449.pdf. Accessed: 
March 29, 2019.
3 Wojciechowska u, olasek P, Czauderna K, didkowska J. Cancer 
in Poland in 2014. K national Cancer registry, 2016 [in Polish]. 
Available from: http://onkologia.org.pl/wp-content/uploads/
nowotwory2014.pdf. Accessed: March 29, 2019.
4 Anderson-hanley C, Sherman Ml, riggs r, Agocha Vb, Compas 
bE. neuropsychological effects of treatments for adults with 
cancer: a meta-analysis and review of the literature. J Int 
neuropsychol Soc. 2003;9:967-82. Medline:14738279 doi:10.1017/
S1355617703970019
5 bury M. Chemobrain in patients suffering from cancer based 
on the example of multiple myeloma. Curr Probl Psychiatry. 
2017;18:62-9. doi:10.1515/cpp-2017-0006
6 Szafryna-Kliwicka A. Cognitive disorders induced systemic 
antineoplastic therapy. In: Talarowska M, Gałecki P, eds. Cognitive 
impairment in selected somatic diseases. Wrocław: Wydawnictwo 
Continuo; 2013. p. 79–87.
7 Ahles TA, root JC, ryan El. Cancer- and cancer treatment-
associated cognitive change: an update on the state of the science. 
J Clin oncol. 2012;30:3675-86. Medline:23008308 doi:10.1200/
JCo.2012.43.0116
8 Sesiuk A, rzepiela l. Selected psychiatric disorders in the course 
of neoplastic diseases. Psychiatr Psychol Klin. 2016;16:21-6. 
doi:10.15557/PiPK.2016.0004
9 Cheung YT, ng T, Shwe M, ho hK, Foo KM, Cham MT, et al. 
Association of proinflammatory cytokines and chemotherapy-
associated cognitive impairment in breast cancer patients: a multi-
centered, prospective, cohort study. Ann oncol. 2015;26:1446-51. 
Medline:25922060 doi:10.1093/annonc/mdv206
10 Penson rT, Kronish K, duan Z, Feller AJ, Stark P, Cook SE, et al. 
Cytokines Il-1beta, Il-2, Il-6, Il-8, MCP-1, GM-CSF and TnFalpha 
in patients with epithelial ovarian cancer and their relationship 
to treatment with paclitaxel. Int J Gynecol Cancer. 2000;10:33-41. 
Medline:11240649 doi:10.1046/j.1525-1438.2000.00003.x
11 Marsland Al, Gianaros PJ, Abramowitch SM, Manuck Sb, hariri Ar. 
Interleukin-6 covaries inversely with hippocampal grey matter 
volume in middle-aged adults. biol Psychiatry. 2008;64:484-90. 
Medline:18514163 doi:10.1016/j.biopsych.2008.04.016
12 Talarowska M, Zajączkowska M, Gałecki P. Cognitive functions 
in first-episode depression and recurrent depressive disorder. 
Psychiatr danub. 2015;27:38-43. Medline:25751430
13 Talarowska M, Gałecki P, Maes M, bobińska K, Kowalczyk E. 
Total antioxidant status correlates with cognitive impairment 
in patients with recurrent depressive disorder. neurochem res. 
2012;37:1761-7. Medline:22562440 doi:10.1007/s11064-012-0788-z
14 hamilton M. A rating scale for depression. J neurol neurosurg 
Psychiatry. 1960;23:56-62. Medline:14399272 doi:10.1136/
jnnp.23.1.56
15 Kessler rC, ustün Tb. The World Mental health (WMh) Survey 
Initiative Version of the World health organization (Who) 
Composite International diagnostic Interview (CIdI). Int J Methods 
Psychiatr res. 2004;13:93-121. Medline:15297906 doi:10.1002/
mpr.168
16 Talarowska M, Szemraj J, Gałecki P. The role of interleukin 
genes in the course of depression. open Med. 2016;11:41-8. 
Medline:28352765 doi:10.1515/med-2016-0009
17 Kirkwood b, Sterne J. Essential medical statistics, 2nd edition. 
Wiley-bleckwell; 2003.
18 Massie MJ. Prevalence of depression in patients with cancer. 
J natl Cancer Inst Monogr. 2004;32:57-71. Medline:15263042 
doi:10.1093/jncimonographs/lgh014
19 Zielińska-Więczkowska h, betłakowski J. Analysis of the 
severity of depressive states in patients with cancer before and 
during chemotherapy. Wiadomości lekarskie. 2010;63:46-53. 
Medline:20941917
20 Colleoni M, Mandala M, Peruzzotti G, robertson C, bredart A, 
Goldhirsch A. depression and degree of acceptance of adjuvant 
cytotoxic drugs. lancet. 2000;356:1326-7. Medline:11073026 
doi:10.1016/S0140-6736(00)02821-X
21 Medzhitov r, Janeway CA Jr. Innate immune recognition 
and control of adaptive immune responses. Semin Immunol. 
1998;10:351-3. Medline:9799709 doi:10.1006/smim.1998.0136
22 Czerwiec K, Myślińska d, Wądołowska A, ruciński J, Podlacha M, 
Kosiński A, et al. Characteristic of inflammatory mediator – the role 
of inflammatory cytokines. Ann Acad Med Gedan. 2016;46:53-8.
23 Forlenza oV, diniz bS, Talib ll, Mendonça VA, ojopi Eb, Gattaz 
WF, et al. Increased serum Il-1beta level in Alzheimer’s disease 
and mild cognitive impairment. dement Geriatr Cogn disord. 
2009;28:507-12. Medline:19996595 doi:10.1159/000255051
24 ng TP, leong T, Chiam PC, Kua Eh. Ethnic variations in 
dementia: the contributions of cardiovascular, psychosocial 
and neuropsychological factors. dement Geriatr Cogn disord. 
2010;29:131-8. Medline:20145399 doi:10.1159/000275668
25 Cibelli M, Fidalgo Ar, Terrando n, Ma d, Monaco C, Feldmann M, et 
al. role of interleukin-1β in postoperative cognitive dysfunction. 
Ann neurol. 2010;68:360-8. Medline:20818791 doi:10.1002/
ana.22082
26 Wilson CJ, Finch CE, Cohen hJ. Cytokines and cognition–the 
173Jasionowska et al: Cognitive functions and depression in cancer
www.cmj.hr
case for a head-to-toe inflammatory paradigm. J Am Geriatr 
Soc. 2002;50:2041-56. Medline:12473019 doi:10.1046/j.1532-
5415.2002.50619.x
27 Meyers CA, Albitar M, Estey E. Cognitive impairment, fatigue, 
and cytokine levels in patients with acute myelogenous 
leukemia or myelodysplastic syndrome. Cancer. 2005;104:788-93. 
Medline:15973668 doi:10.1002/cncr.21234
28 hermelink K, untch M, lux MP, Kreienberg r, beck T, bauerfeind I, 
et al. Cognitive function during neoadjuvant chemotherapy for 
breast cancer: results of a prospective, multicenter, longitudinal 
study. Cancer. 2007;109:1905-13. Medline:17351951 doi:10.1002/
cncr.22610
29 Andryszak P, Izdebski P, Tujakowski J. The influence of adjuvant 
chemotherapy on cognitive functioning of women with breast 
cancer: a literature review. J oncol. 2012;62:291-304.
30 bury M, borkowska Ar, daniluk b. Impact of chemotherapy on 
memory, attention and executive functions depending on the 
stages of treatment and the level of depression in female patients 
with cancer. Acta neuropsychol. 2014;12:417-27.
31 Wefel JS, lenzi r, Theriault r, buzdar Au, Cruickshank S, Meyers 
CA. “Chemobrain” in breast carcinoma?: a prologue. Cancer. 
2004;101:466-75. Medline:15274059 doi:10.1002/cncr.20393
32 Jansen CE, dodd MJ, Miaskowski CA, dowling GA, Kramer J. 
Preliminary results of a longitudinal study of changes in cognitive 
function in breast cancer patients undergoing chemotherapy 
with doxorubicin and cyclophosphamide. Psychooncology. 
2008;17:1189-95. Medline:18506671 doi:10.1002/pon.1342
33 Cherrier MM, Aubin S, higano CS. Cognitive and mood changes in 
men undergoing intermittent combined androgen blockade for 
non-metastatic prostate cancer. Psychooncology. 2009;18:237-47. 
Medline:18636420 doi:10.1002/pon.1401
34 Castellon SA, Ganz PA, bower JE, Petersen l, Abraham l, 
Greendale GA. neurocognitive performance in breast cancer 
survivors exposed to adjuvant chemotherapy and tamoxifen. 
J Clin Exp neuropsychol. 2004;26:955-69. Medline:15742545 
doi:10.1080/13803390490510905
35 downie FP, Mar Fan hG, houédé-Tchen n, Yi Q, Tannock IF. 
Cognitive function, fatigue, and menopausal symptoms in breast 
cancer patients receiving adjuvant chemotherapy: evaluation 
with patient interview after formal assessment. Psychooncology. 
2006;15:921-30. Medline:16477674 doi:10.1002/pon.1035
36 Janelsins MC, Mustian KM, Palesh oG, Mohile SG, Peppone lJ, 
Sprod lK, et al. differential expression of cytokines in breast 
cancer patients receiving different chemotherapies: implications 
for cognitive impairment research. Support Care Cancer. 
2012;20:831-9. Medline:21533812 doi:10.1007/s00520-011-1158-0
37 Cheung YT, lim Sr, ho hK, Chan A. Cytokines as mediators 
of chemotherapy-associated cognitive changes: current 
evidence, limitations and directions for future research. PloS 
one. 2013;8:e81234. Medline:24339912 doi:10.1371/journal.
pone.0081234
38 Argyriou AA, Assimakopoulos K, Iconomou G, Giannakopoulou 
F, Kalofonos hP. Either called “chemobrain” or “chemofog,” the 
long-term chemotherapy-induced cognitive decline in cancer 
survivors is real. J Pain Symptom Manage. 2011;41:126-39. 
Medline:20832978 doi:10.1016/j.jpainsymman.2010.04.021
39 de ruiter Mb, reneman l, boogerd W, Veltman dJ, van dam FS, 
nederveen AJ, et al. Cerebral hyporesponsiveness and cognitive 
impairment 10 years after chemotherapy for breast cancer. hum 
brain Mapp. 2011;32:1206-19. Medline:20669165 doi:10.1002/
hbm.21102
